Cogent Biosciences (COGT) Financials

Cogent Biosciences logo
$26.72 -1.02 (-3.66%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Cogent Biosciences

Annual Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-26 -35 -32 -179 -72 -140 -192 -256 -329
Consolidated Net Income / (Loss)
-25 -35 -32 -75 -72 -140 -192 -256 -329
Net Income / (Loss) Continuing Operations
-25 -35 -32 -118 -73 -142 -192 -256 -329
Total Pre-Tax Income
-25 -35 -32 -118 -73 -142 -192 -256 -329
Total Operating Income
-26 -36 -32 -82 -76 -148 -208 -276 -333
Total Gross Profit
8.36 9.73 22 7.87 0.00 0.00 0.00 0.00 0.00
Total Revenue
8.36 9.73 22 7.87 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
35 46 55 133 76 148 208 276 333
Selling, General & Admin Expense
4.68 7.45 11 17 20 26 34 43 64
Research & Development Expense
30 38 44 26 56 122 174 233 270
Total Other Income / (Expense), net
0.66 1.47 0.35 7.39 3.28 7.60 16 20 4.43
Interest Expense
- - - - - - 0.00 0.00 10
Interest & Investment Income
0.39 1.15 0.27 0.14 0.47 3.99 13 18 15
Other Income / (Expense), net
0.27 0.32 0.08 7.25 2.47 2.25 2.64 1.99 -0.02
Basic Earnings per Share
($2.51) ($1.39) ($4.18) ($16.17) ($1.87) ($433.56) ($1.94) ($2,426.26) ($2,696.92)
Weighted Average Basic Shares Outstanding
10.19M 24.90M 7.62M 11.08M 38.73M 58.83M 79.66M 103.94M 128.97M
Diluted Earnings per Share
($2.51) ($1.39) ($4.18) ($16.17) ($1.87) ($433.56) ($1.94) ($2,426.26) ($2,696.92)
Weighted Average Diluted Shares Outstanding
10.19M 24.90M 7.62M 11.08M 38.73M 58.83M 79.66M 103.94M 128.97M
Weighted Average Basic & Diluted Shares Outstanding
10.19M 24.90M 7.62M 11.08M 38.73M 69.95M 103.91M 113.85M 162.31M

Quarterly Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 83 - - - 117
Net Income / (Loss) Attributable to Common Shareholders
-58 -59 -71 -68 -72 -74 -81 -102 -97 -96 -111
Consolidated Net Income / (Loss)
-58 -59 -71 -68 -72 -74 -81 -102 -97 -96 -111
Net Income / (Loss) Continuing Operations
-58 -59 -71 -68 -72 -74 -81 -103 -97 -96 -111
Total Pre-Tax Income
-58 -59 -71 -68 -72 -74 -81 -103 -97 -96 -111
Total Operating Income
-62 -64 -75 -74 -75 -76 -83 -99 -104 -103 -117
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
62 64 75 74 75 76 83 99 104 103 117
Selling, General & Admin Expense
9.70 10 12 12 12 13 14 24 28 32 42
Research & Development Expense
53 54 64 62 63 62 69 76 75 71 75
Total Other Income / (Expense), net
4.06 5.44 4.78 5.81 2.95 2.05 2.43 -3.00 6.26 6.23 5.76
Interest Expense
- - - - 0.00 0.31 1.46 - 1.21 1.22 1.24
Interest & Investment Income
4.06 5.39 4.78 3.86 2.95 2.37 3.89 5.48 7.61 7.46 7.05
Other Income / (Expense), net
-0.00 0.04 0.00 1.95 -0.01 -0.01 -0.00 -0.01 -0.14 -0.01 -0.05
Basic Earnings per Share
($607.97) ($540.34) ($651.92) ($2,424.41) ($656.64) ($665.37) ($627.84) ($1,374.41) ($663.45) ($650.67) ($743.50)
Weighted Average Basic Shares Outstanding
94.89M 99.33M 110.25M 103.94M 113.38M 114.54M 137.62M 128.97M 162.27M 171.05M 173.17M
Diluted Earnings per Share
($607.97) ($540.34) ($651.92) ($2,424.41) ($656.64) ($665.37) ($627.84) ($1,374.41) ($663.45) ($650.67) ($743.50)
Weighted Average Diluted Shares Outstanding
94.89M 99.33M 110.25M 103.94M 113.38M 114.54M 137.62M 128.97M 162.27M 171.05M 173.17M
Weighted Average Basic & Diluted Shares Outstanding
95.61M 109.45M 110.46M 113.85M 113.86M 139.70M 142.38M 162.31M 170.87M 173.52M 173.99M

Annual Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-13 27 -18 205 -23 -80 -88 45 214
Net Cash From Operating Activities
-26 -32 -42 -36 -59 -119 -154 -208 -264
Net Cash From Continuing Operating Activities
-26 -32 -42 -36 -59 -119 -154 -208 -264
Net Income / (Loss) Continuing Operations
-25 -35 -32 -75 -72 -140 -192 -256 -329
Consolidated Net Income / (Loss)
-25 -35 -32 -75 -72 -140 -192 -256 -329
Depreciation Expense
1.17 1.32 1.29 0.72 0.15 0.84 2.27 2.45 2.56
Amortization Expense
0.02 -0.25 -0.05 - 1.84 3.40 -3.86 -5.72 0.66
Non-Cash Adjustments To Reconcile Net Income
1.35 3.12 3.06 43 12 18 31 40 53
Changes in Operating Assets and Liabilities, net
-2.88 -2.15 -14 -4.96 -0.17 -0.61 9.74 12 8.01
Net Cash From Investing Activities
14 -11 23 8.42 -1.72 -125 -98 38 -400
Net Cash From Continuing Investing Activities
14 -11 23 8.42 -1.72 -125 -98 38 -400
Purchase of Property, Plant & Equipment
-0.91 -0.55 - 0.00 -1.72 -6.86 -2.80 -0.57 -1.55
Purchase of Investments
-6.50 -48 - - 0.00 -178 -349 -256 -687
Sale and/or Maturity of Investments
21 38 23 - 0.00 60 254 294 289
Net Cash From Financing Activities
-0.73 70 0.11 232 38 164 164 214 878
Net Cash From Continuing Financing Activities
-0.73 70 0.11 232 38 164 164 214 878
Repayment of Debt
- - - - - - 0.00 0.00 166
Repurchase of Preferred Equity
- - - - - - - - 0.00
Issuance of Debt
- - - - - - 0.00 0.00 49
Issuance of Common Equity
0.06 72 0.00 133 38 162 163 214 700
Other Financing Activities, net
- - 0.11 0.51 -0.06 1.26 0.97 0.20 -37
Cash Interest Paid
- - - - - - 0.00 0.00 2.02

Quarterly Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
163 -128 8.83 1.12 28 1.60 -1.97 187 -71 -60 36
Net Cash From Operating Activities
-53 -43 -52 -61 -67 -55 -64 -79 -87 -77 -81
Net Cash From Continuing Operating Activities
-53 -43 -52 -61 -67 -55 -64 -79 -87 -77 -81
Net Income / (Loss) Continuing Operations
-58 -59 -71 -68 -72 -74 -81 -102 -97 -96 -111
Consolidated Net Income / (Loss)
-58 -59 -71 -68 -72 -74 -81 -102 -97 -96 -111
Depreciation Expense
0.60 0.61 0.62 0.63 0.64 0.66 0.64 0.63 0.63 0.74 0.57
Amortization Expense
-0.93 3.06 -5.72 -2.12 -0.46 0.78 0.64 -0.31 -0.37 -0.05 1.05
Non-Cash Adjustments To Reconcile Net Income
9.39 10 10 9.98 10 9.72 11 23 17 17 17
Changes in Operating Assets and Liabilities, net
-3.24 2.58 13 -1.13 -4.72 7.84 4.76 0.13 -6.83 1.34 12
Net Cash From Investing Activities
1.04 -85 60 62 69 8.91 -155 -323 -36 14 37
Net Cash From Continuing Investing Activities
1.04 -85 60 62 69 8.91 -155 -323 -36 14 37
Purchase of Property, Plant & Equipment
-0.07 -0.15 -0.28 -0.08 -0.55 -0.13 -0.07 -0.81 -0.45 -0.37 -0.11
Purchase of Investments
-73 -150 -19 -13 0.00 -68 -224 -395 -134 -83 -74
Sale and/or Maturity of Investments
74 66 80 74 70 77 69 73 98 97 111
Net Cash From Financing Activities
214 -0.26 0.62 0.03 25 47 217 589 53 2.96 80
Net Cash From Continuing Financing Activities
214 -0.26 0.62 0.03 25 47 217 589 53 2.96 80
Issuance of Common Equity
214 -0.37 0.56 -0.00 25 - 217 459 47 - 73
Other Financing Activities, net
0.00 0.11 0.06 0.03 0.14 0.01 1.04 -39 5.76 2.96 6.68

Annual Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
49 86 49 251 232 301 313 328 938
Total Current Assets
42 81 41 245 223 265 271 296 910
Cash & Equivalents
28 56 37 242 220 140 53 98 312
Short-Term Investments
13 23 - - 0.00 119 212 189 589
Prepaid Expenses
0.51 0.74 1.17 2.72 2.95 4.44 5.06 9.40 9.59
Plant, Property, & Equipment, net
4.11 3.25 1.87 0.13 1.71 7.78 8.34 6.47 5.46
Total Noncurrent Assets
2.63 1.67 6.97 5.87 7.75 28 34 25 22
Long-Term Investments
- - - - - 0.00 7.46 0.00 0.00
Other Noncurrent Operating Assets
2.63 1.67 6.97 5.87 7.75 28 27 25 22
Total Liabilities & Shareholders' Equity
49 86 49 251 232 301 313 328 938
Total Liabilities
21 26 18 16 18 45 56 72 301
Total Current Liabilities
11 25 13 13 17 27 38 56 64
Accounts Payable
1.35 1.52 3.18 0.73 3.48 5.84 11 12 9.50
Accrued Expenses
2.95 5.48 7.13 4.78 8.21 18 26 42 53
Other Current Liabilities
- - 1.62 7.58 5.38 3.12 1.39 1.57 1.55
Total Noncurrent Liabilities
9.62 0.75 4.41 3.16 0.83 18 17 16 237
Long-Term Debt
- - - - - - - 0.00 223
Other Noncurrent Operating Liabilities
- - 4.41 3.16 0.83 18 17 16 14
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-49 60 32 235 214 256 258 256 636
Total Preferred & Common Equity
-49 60 32 235 214 256 258 256 636
Preferred Stock
0.00 0.00 0.00 111 85 66 60 111 89
Total Common Equity
-49 60 32 124 129 190 198 146 547
Common Stock
2.51 152 156 322 400 601 801 1,005 1,735
Retained Earnings
-51 -92 -124 -199 -271 -411 -604 -859 -1,188
Accumulated Other Comprehensive Income / (Loss)
-0.02 -0.01 - - 0.00 -0.10 0.25 0.45 0.36

Quarterly Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
392 355 476 430 384 284 275 426 903 835 832
Total Current Assets
335 286 442 370 342 253 245 397 878 805 804
Cash & Equivalents
214 87 216 88 97 126 128 125 241 181 217
Short-Term Investments
115 192 220 275 238 120 110 266 625 611 574
Prepaid Expenses
5.12 6.91 6.16 6.76 6.01 7.22 7.16 6.35 11 13 12
Plant, Property, & Equipment, net
9.10 8.64 7.82 7.36 7.02 6.45 5.85 5.27 5.30 4.78 4.31
Total Noncurrent Assets
49 61 26 53 35 24 24 23 20 25 24
Long-Term Investments
22 34 0.00 27 10 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
27 27 26 26 25 24 24 23 20 25 24
Total Liabilities & Shareholders' Equity
392 355 476 430 384 284 275 426 903 835 832
Total Liabilities
44 53 54 57 69 65 120 123 295 302 316
Total Current Liabilities
26 35 37 40 53 49 58 62 58 59 73
Accounts Payable
7.16 9.87 16 8.98 15 14 17 16 14 7.49 5.94
Accrued Expenses
17 24 20 30 36 34 40 45 43 50 66
Other Current Liabilities
1.18 1.34 1.43 1.48 1.52 1.61 1.66 1.71 1.38 1.49 1.58
Total Noncurrent Liabilities
18 18 17 17 16 15 61 61 237 243 243
Long-Term Debt
- - - - - - 44 44 223 223 224
Other Noncurrent Operating Liabilities
18 18 17 17 16 15 17 17 14 19 19
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
348 303 422 373 315 219 155 302 608 532 516
Total Preferred & Common Equity
348 303 422 373 315 219 155 302 608 532 516
Preferred Stock
62 60 222 114 111 108 108 108 65 65 65
Total Common Equity
286 243 200 259 204 111 47 195 543 468 452
Common Stock
780 792 862 980 995 1,042 1,052 1,280 1,829 1,851 1,946
Retained Earnings
-494 -549 -662 -721 -792 -931 -1,005 -1,086 -1,286 -1,382 -1,494
Accumulated Other Comprehensive Income / (Loss)
-0.10 -0.17 -0.04 -0.19 0.90 0.16 0.01 0.21 -0.42 -0.77 -0.72

Annual Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - -
Revenue Growth
0.00% 16.44% 131.14% -65.02% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -40.18% 10.84% -140.54% 4.23% -98.83% -48.63% -31.95% -19.10%
EBIT Growth
0.00% -37.90% 10.05% -133.50% 2.49% -99.21% -42.31% -32.22% -21.70%
NOPAT Growth
0.00% -37.68% 10.63% -155.45% 8.09% -95.68% -40.78% -32.58% -20.81%
Net Income Growth
0.00% -35.46% 7.82% -135.00% 3.39% -94.04% -37.20% -32.98% -28.56%
EPS Growth
0.00% 44.62% 7.82% -286.84% 88.44% -23,085.03% -12.60% -397.01% -11.16%
Operating Cash Flow Growth
0.00% -25.76% -27.78% 13.64% -63.91% -101.89% -29.49% -35.26% -27.26%
Free Cash Flow Firm Growth
0.00% 0.00% -79.94% -58.08% 1.38% -89.75% -29.68% -31.54% -25.27%
Invested Capital Growth
0.00% -44.21% 69.16% -32.87% 26.89% 12.80% -220.43% -100.36% -34.78%
Revenue Q/Q Growth
0.00% 20.89% 104.24% -66.01% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -7.03% 26.93% -10.00% -20.43% -15.07% -11.36% -3.17% -8.51%
EBIT Q/Q Growth
0.00% -6.65% 26.07% -9.41% -23.60% -13.86% -8.85% -4.52% -9.07%
NOPAT Q/Q Growth
0.00% -6.27% 25.89% -19.99% -23.11% -13.96% -7.48% -5.95% -8.37%
Net Income Q/Q Growth
0.00% -5.87% 25.51% -22.29% -23.12% -11.71% -8.30% -5.60% -11.74%
EPS Q/Q Growth
0.00% -27.52% 25.51% -121.81% 51.17% -23,986.67% -23,597.57% -97,340.16% -38.41%
Operating Cash Flow Q/Q Growth
0.00% -8.35% 1.37% -2.64% -24.10% -7.85% -10.55% -8.63% -7.53%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -7.63% -7.39% -8.37% -8.47% -7.22% -10.15% -10.20%
Invested Capital Q/Q Growth
0.00% 6.27% 67.19% 43.70% 2.65% -1,078.38% -54.65% 0.32% 6.06%
Profitability Metrics
- - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-295.33% -355.56% -137.16% -943.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-312.82% -369.89% -143.02% -1,044.33% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-309.55% -366.60% -142.67% -952.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-304.93% -354.76% -141.49% -950.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 63.41% 99.53% 99.04% 99.12% 100.00% 100.00%
Interest Burden Percent
98.51% 96.77% 99.17% 157.39% 99.36% 97.26% 93.69% 93.40% 98.67%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-90.06% -78.00% -69.21% -56.16% -32.20% -59.69% -74.94% -99.54% -73.70%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-52.69% -52.85% -47.43% -49.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-51.90% -51.14% -47.04% -49.82% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
155.42% -10.03% -69.21% -32.79% -18.12% -40.48% -56.57% -66.50% -57.19%
Return on Equity Simple (ROE_SIMPLE)
52.19% -57.33% -100.22% -31.88% -33.74% -54.84% -74.63% -99.83% 0.00%
Net Operating Profit after Tax (NOPAT)
-18 -25 -23 -58 -53 -103 -146 -193 -233
NOPAT Margin
-218.98% -258.92% -100.11% -731.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-17.51% -15.60% -16.05% -12.35% -8.40% -15.31% -17.51% -22.38% -19.81%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -40.47% -56.51% -75.37% -27.16%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
55.98% 76.58% 48.75% 221.34% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
356.84% 393.31% 194.27% 327.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
412.82% 469.89% 243.02% 1,692.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-26 -36 -32 -75 -73 -146 -207 -274 -333
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-25 -35 -31 -74 -71 -141 -210 -277 -330
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
0.00 2.19 0.70 0.26 2.66 4.25 2.56 5.91 9.25
Price to Tangible Book Value (P/TBV)
0.00 2.19 0.70 0.26 2.66 4.25 2.56 5.91 9.25
Price to Revenue (P/Rev)
8.28 13.56 0.98 4.05 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
12.60 5.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35
Financial Leverage
-1.45 -1.35 -1.26 -1.05 -1.03 -1.02 -1.04 -1.09 -1.08
Leverage Ratio
1.74 1.53 1.47 1.13 1.08 1.13 1.20 1.25 1.42
Compound Leverage Factor
1.71 1.48 1.46 1.77 1.07 1.10 1.12 1.17 1.40
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.94%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.94%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 47.25% 39.87% 25.74% 23.29% 43.15% 10.40%
Noncontrolling Interests to Total Capital
272.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-172.57% 100.00% 100.00% 52.75% 60.13% 74.26% 76.71% 56.85% 63.66%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.68
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.05
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.68
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.96
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.90
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.96
Altman Z-Score
-0.27 1.11 -3.78 0.22 9.85 8.19 1.47 1.67 8.21
Noncontrolling Interest Sharing Ratio
272.57% 87.14% 0.00% 41.62% 43.73% 32.18% 24.51% 33.19% 22.40%
Liquidity Ratios
- - - - - - - - -
Current Ratio
3.79 3.25 3.06 18.70 13.04 9.87 7.09 5.32 14.23
Quick Ratio
3.73 3.22 2.98 18.50 12.86 9.66 6.96 5.15 14.08
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -20 -35 -56 -55 -104 -135 -178 -223
Operating Cash Flow to CapEx
-2,832.79% -5,917.85% 0.00% 0.00% -3,418.44% -1,728.66% -5,494.42% -36,263.70% -17,016.99%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21.74
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -25.82
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -25.97
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.17 0.14 0.33 0.05 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
10.07 7.79 12.27 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.04 2.65 8.80 7.87 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
36.24 46.83 29.75 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
36.24 46.83 29.75 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
-13 -18 -5.66 -7.52 -5.50 -4.80 -15 -31 -41
Invested Capital Turnover
-0.66 -0.63 -1.87 -1.19 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 -5.63 13 -1.86 2.02 0.70 -11 -15 -11
Enterprise Value (EV)
105 53 -15 -99 208 613 293 685 4,469
Market Capitalization
69 132 22 32 342 808 506 862 5,057
Book Value per Share
($4.79) $2.01 $1.04 $10.91 $3.23 $2.72 $2.30 $1.32 $3.84
Tangible Book Value per Share
($4.79) $2.01 $1.04 $10.91 $3.23 $2.72 $2.30 $1.32 $3.84
Total Capital
28 60 32 235 214 256 258 256 859
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 223
Net Debt
-41 -79 -37 -242 -220 -261 -273 -287 -678
Capital Expenditures (CapEx)
0.91 0.55 -0.24 -0.32 1.72 6.86 2.80 0.57 1.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-9.85 -23 -10 -10 -14 -22 -33 -46 -54
Debt-free Net Working Capital (DFNWC)
31 56 27 232 206 238 233 241 846
Net Working Capital (NWC)
31 56 27 232 206 238 233 241 846
Net Nonoperating Expense (NNE)
7.19 9.33 9.31 17 19 37 47 63 96
Net Nonoperating Obligations (NNO)
-41 -79 -37 -242 -220 -261 -273 -287 -678
Total Depreciation and Amortization (D&A)
1.19 1.08 1.24 0.72 1.99 4.24 -2.90 -3.27 3.22
Debt-free, Cash-free Net Working Capital to Revenue
-117.79% -231.53% -44.81% -131.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
373.07% 575.89% 121.53% 2,945.22% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
373.07% 575.89% 121.53% 2,945.22% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
($10.04) ($5.56) ($4.16) ($16.17) ($1.87) ($2.39) ($2.42) ($2,426.26) ($2,696.92)
Adjusted Weighted Average Basic Shares Outstanding
2.55M 7.52M 7.65M 37.19M 45.81M 58.74M 79.66M 103.94M 128.97M
Adjusted Diluted Earnings per Share
($10.04) ($5.56) ($4.16) ($16.17) ($1.87) ($2.39) ($2.42) ($2,426.26) ($2,696.92)
Adjusted Weighted Average Diluted Shares Outstanding
2.55M 7.52M 7.65M 37.19M 45.81M 58.74M 79.66M 103.94M 128.97M
Adjusted Basic & Diluted Earnings per Share
($10.04) ($5.56) ($4.16) ($16.17) ($1.87) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.55M 6.22M 7.62M 11.08M 38.73M 69.95M 103.91M 113.85M 162.31M
Normalized Net Operating Profit after Tax (NOPAT)
-18 -25 -23 -58 -53 -103 -146 -193 -233
Normalized NOPAT Margin
-218.98% -258.92% -100.11% -731.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-304.93% -354.76% -141.49% -1,498.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -32.55
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.78
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -32.70
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -22.93
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-3.10% -5.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 162,308,820.00 170,868,004.00 173,524,982.00
DEI Adjusted Shares Outstanding
- - - - - - - - 162,308,820.00 170,868,004.00 173,524,982.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - -0.60 -0.56 -0.64
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-52.36% -30.96% -39.26% -13.16% -19.16% -22.20% -1.94% -35.33% -38.44% -37.50% -40.86%
EBIT Growth
-52.75% -37.44% -26.57% -19.77% -20.08% -17.48% -10.54% -38.61% -38.44% -35.80% -40.64%
NOPAT Growth
-44.33% -36.75% -26.58% -26.63% -20.08% -17.39% -10.53% -34.94% -38.27% -35.80% -40.58%
Net Income Growth
-51.21% -33.75% -27.54% -24.95% -23.37% -24.73% -14.58% -50.89% -35.24% -31.11% -37.68%
EPS Growth
-12.73% 0.00% 0.00% -398.45% -8.01% -23.14% 99.92% -119.54% -1.04% 2.21% -18.42%
Operating Cash Flow Growth
-32.93% -33.17% -36.90% -37.46% -26.62% -27.73% -23.67% -30.59% -30.63% -41.67% -25.67%
Free Cash Flow Firm Growth
20.46% 18.56% 1.05% -19.89% -38.82% 0.48% -41.53% -62.85% -62.47% -141.67% -66.60%
Invested Capital Growth
-755.87% -571.81% -210.85% -100.36% -98.91% -132.98% -43.02% -34.78% -33.17% 6.20% -15.75%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
3.13% 3.27% -32.69% 8.98% -2.01% 0.81% -10.69% -20.83% -4.35% 1.49% -13.39%
EBIT Q/Q Growth
-4.12% -3.11% -17.20% 4.81% -4.39% -0.87% -10.28% -19.36% -4.27% 1.06% -14.21%
NOPAT Q/Q Growth
-7.17% -3.18% -17.13% 2.23% -1.63% -0.87% -10.28% -19.36% -4.14% 0.94% -14.17%
Net Income Q/Q Growth
-7.33% -1.03% -19.82% 3.83% -5.98% -2.14% -10.07% -26.64% 5.02% 0.97% -15.58%
EPS Q/Q Growth
3.13% 4.84% -8.47% -378,714.06% 72.92% -1.33% 99.92% -274,782.00% 51.73% 1.93% -14.27%
Operating Cash Flow Q/Q Growth
-19.19% 18.71% -21.74% -16.53% -9.80% 18.00% -17.87% -23.05% -9.83% 11.06% -4.55%
Free Cash Flow Firm Q/Q Growth
6.48% -9.35% -3.13% -13.67% -8.30% 21.61% -46.66% -30.79% -8.05% -16.61% -1.10%
Invested Capital Q/Q Growth
12.77% -24.43% -85.17% 0.32% 13.40% -45.74% -13.67% 6.06% 14.43% -2.66% -40.26%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.43% 100.00% 99.69% 100.00% 100.00% 100.00%
Interest Burden Percent
93.50% 91.62% 93.66% 94.62% 96.06% 96.86% 97.09% 103.32% 93.84% 93.92% 95.05%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-65.70% -62.92% -78.47% -99.54% -84.04% -107.55% -95.40% -73.70% -85.72% -109.74% -99.59%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-36.76% -47.54% -56.79% -66.50% -40.76% -62.35% -61.62% -57.19% -67.79% -82.17% -78.59%
Return on Equity Simple (ROE_SIMPLE)
-50.24% -60.83% -77.00% 0.00% -123.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-44 -45 -53 -52 -52 -53 -58 -70 -73 -72 -82
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.46% -3.75% -5.42% -5.82% -5.73% -7.06% -6.52% -6.81% -5.59% -6.44% -6.43%
Return On Investment Capital (ROIC_SIMPLE)
- - - -20.14% -23.95% -26.59% -16.83% -8.11% -8.73% -9.51% -11.08%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-62 -64 -75 -72 -75 -76 -83 -99 -104 -103 -117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-63 -61 -81 -73 -75 -74 -82 -99 -103 -102 -116
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.89 3.11 5.79 5.91 6.15 17.35 10.31 9.25 11.51 14.14 12.31
Price to Tangible Book Value (P/TBV)
2.89 3.11 5.79 5.91 6.15 17.35 10.31 9.25 11.51 14.14 12.31
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.28 0.15 0.35 0.37 0.42 0.43
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.28 0.15 0.35 0.37 0.42 0.43
Financial Leverage
-1.02 -1.03 -1.07 -1.09 -1.06 -1.11 -1.12 -1.08 -1.08 -1.11 -1.12
Leverage Ratio
1.14 1.14 1.20 1.25 1.18 1.33 1.31 1.42 1.44 1.61 1.54
Compound Leverage Factor
1.07 1.04 1.12 1.18 1.14 1.29 1.27 1.46 1.35 1.52 1.46
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 22.09% 12.76% 25.94% 26.86% 29.56% 30.24%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 22.09% 12.76% 25.94% 26.86% 29.56% 30.24%
Preferred Equity to Total Capital
52.60% 30.58% 35.15% 43.15% 49.39% 54.23% 31.13% 10.40% 7.79% 8.57% 8.75%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
47.40% 69.42% 64.85% 56.85% 50.61% 23.68% 56.11% 63.66% 65.35% 61.87% 61.01%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.15 -0.15 -0.68 -0.62 -0.58 -0.53
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.64 1.14 2.05 1.79 1.47 1.35
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.15 -0.15 -0.68 -0.62 -0.58 -0.53
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.21 -0.21 -0.96 -0.88 -0.82 -0.76
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.92 1.61 2.90 2.54 2.09 1.92
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.21 -0.21 -0.96 -0.88 -0.82 -0.76
Altman Z-Score
5.10 6.61 7.59 3.71 1.71 -1.12 6.48 9.03 11.41 11.48 8.63
Noncontrolling Interest Sharing Ratio
44.04% 24.45% 27.63% 33.19% 51.51% 42.03% 35.41% 22.40% 20.92% 25.12% 21.09%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
12.05 9.25 6.44 5.32 5.13 4.19 6.38 14.23 15.14 13.57 10.99
Quick Ratio
11.88 9.08 6.32 5.15 4.98 4.07 6.28 14.08 14.94 13.36 10.82
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-28 -31 -32 -36 -39 -31 -45 -59 -64 -74 -75
Operating Cash Flow to CapEx
-75,041.43% -28,852.03% -18,565.71% -80,769.33% -12,159.23% -41,635.11% -98,901.54% -9,754.01% -19,350.33% -20,884.05% -74,802.78%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -30.89 0.00 -52.50 -61.01 -60.40
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -44.06 0.00 -71.63 -63.49 -64.99
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -44.11 0.00 -72.00 -63.80 -65.08
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-13 -17 -31 -31 -27 -39 -44 -41 -36 -36 -51
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-15 -14 -21 -15 -13 -22 -13 -11 -8.85 2.41 -6.96
Enterprise Value (EV)
365 530 947 685 544 732 1,767 4,469 5,669 6,109 5,054
Market Capitalization
579 806 1,182 862 682 817 2,006 5,057 6,247 6,613 5,556
Book Value per Share
$2.11 $2.71 $1.86 $1.32 $0.97 $0.41 $1.39 $3.84 $3.35 $2.74 $2.60
Tangible Book Value per Share
$2.11 $2.71 $1.86 $1.32 $0.97 $0.41 $1.39 $3.84 $3.35 $2.74 $2.60
Total Capital
422 373 315 256 219 199 347 859 831 756 740
Total Debt
0.00 0.00 0.00 0.00 0.00 44 44 223 223 223 224
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 44 44 223 223 223 224
Net Debt
-436 -390 -346 -287 -246 -194 -347 -678 -643 -569 -567
Capital Expenditures (CapEx)
0.07 0.15 0.28 0.08 0.55 0.13 0.07 0.81 0.45 0.37 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-31 -33 -47 -46 -42 -51 -56 -54 -47 -47 -61
Debt-free Net Working Capital (DFNWC)
405 330 288 241 204 187 335 846 820 746 730
Net Working Capital (NWC)
405 330 288 241 204 187 335 846 820 746 730
Net Nonoperating Expense (NNE)
15 14 18 16 20 21 23 33 25 25 29
Net Nonoperating Obligations (NNO)
-436 -390 -346 -287 -246 -194 -347 -678 -643 -569 -567
Total Depreciation and Amortization (D&A)
-0.33 3.66 -5.10 -1.50 0.18 1.44 1.28 0.32 0.25 0.69 1.62
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.62) ($0.59) ($0.64) ($2,424.41) ($656.64) ($665.37) ($0.50) ($1,374.41) ($663.45) ($650.67) ($743.50)
Adjusted Weighted Average Basic Shares Outstanding
94.80M 99.24M 110.17M 103.94M 113.38M 114.54M 137.55M 128.97M 162.27M 171.05M 173.17M
Adjusted Diluted Earnings per Share
($0.62) ($0.59) ($0.64) ($2,424.41) ($656.64) ($665.37) ($0.50) ($1,374.41) ($663.45) ($650.67) ($743.50)
Adjusted Weighted Average Diluted Shares Outstanding
94.80M 99.24M 110.17M 103.94M 113.38M 114.54M 137.55M 128.97M 162.27M 171.05M 173.17M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
95.61M 109.45M 110.46M 113.85M 113.86M 139.70M 142.38M 162.31M 170.87M 173.52M 173.99M
Normalized Net Operating Profit after Tax (NOPAT)
-44 -45 -53 -52 -52 -53 -58 -70 -73 -72 -82
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -57.13 0.00 -85.53 -84.35 -94.32
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -39.99 0.00 -59.79 -59.04 -65.99
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -57.18 0.00 -85.90 -84.65 -94.40
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -40.04 0.00 -60.16 -59.34 -66.08
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Cogent Biosciences (NASDAQ:COGT) remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is therefore driven primarily by research spending, cash burn, financing activity and the value of its investment portfolio rather than sales or operating profitability.

Liquidity has improved substantially over the longer term, although it declined during the first half of 2026. Cash and short-term investments totaled approximately $792.3 million at June 30, 2026, compared with $237.8 million at June 30, 2025 and $363.2 million at June 30, 2024. However, the combined balance fell from $866.4 million at March 31, 2026, reflecting the company’s continued cash consumption.

Operating cash flow has become increasingly negative. Quarterly operating cash outflows rose from $26.5 million in Q2 2022 to $32.1 million in Q2 2023, $42.7 million in Q2 2024, $54.5 million in Q2 2025 and $77.3 million in Q2 2026. The trend reflects materially higher development costs, with quarterly research and development expense increasing from $29.5 million in Q2 2022 to $70.8 million in Q2 2026.

Cogent has offset part of this burn through equity financing and investment management. The company raised approximately $459.1 million in common equity in Q4 2025 and another $46.8 million in Q1 2026. That funding helped expand its cash and investment holdings, but it also increased the potential for shareholder dilution. Long-term debt stood at $223.5 million at June 30, 2026, up sharply from $44.3 million at September 30, 2025 and zero at March 31, 2025.

  • Strong liquidity position: Cash and short-term investments of approximately $792.3 million provide a substantial financial cushion relative to current liabilities of $59.3 million.
  • Investment income is helping reduce losses: Interest and investment income reached $7.5 million in Q2 2026, compared with $2.4 million in Q2 2023, providing a partial offset to operating expenses.
  • Limited capital expenditure burden: Q2 2026 purchases of property, plant and equipment were only $0.4 million, suggesting that cash use is concentrated in research and development rather than heavy infrastructure spending.
  • Improved balance-sheet scale since 2023: Total assets increased to $834.5 million at June 30, 2026 from $392.4 million at June 30, 2023, supported largely by equity financing and investment holdings.
  • Investment portfolio activity is significant: Cogent purchased $82.8 million of investments and received $97.5 million from investment sales or maturities in Q2 2026. These transactions support liquidity management but do not represent operating revenue.
  • Current liabilities remain manageable: Current assets of $804.8 million were approximately 13.6 times current liabilities of $59.3 million at the end of Q2 2026, although this comparison includes short-term investments rather than cash alone.
  • Persistent operating losses: Cogent reported a net loss of $96.4 million in Q2 2026, following losses of $97.4 million in Q1 2026, $102.5 million in Q4 2025 and $80.9 million in Q3 2025.
  • Operating expenses continue to climb: Quarterly operating expenses rose to $102.6 million in Q2 2026 from $75.6 million in Q2 2025 and $47.1 million in Q2 2023. R&D accounted for $70.8 million of the latest quarter’s expense.
  • Accelerating cash burn: Q2 2026 operating cash outflow of $77.3 million was about 42% higher than the Q2 2025 outflow of $54.5 million. If that quarterly rate persisted, annual operating cash use would approach $309 million before changes in investment activity.
  • Reliance on external capital and dilution risk: Common shares used in the loss-per-share calculation increased from approximately 49.4 million in Q2 2022 to 171.0 million in Q2 2026. The company’s growing debt balance also adds financial obligations before commercial revenue begins.

Overall, Cogent’s balance sheet is considerably stronger than it was several years ago, but the improvement has largely come from capital raises and financing rather than operating performance. For investors, the key questions are whether clinical development can eventually produce commercial revenue and whether the company can slow its rising cash burn before additional equity or debt financing becomes necessary. The provided income statements also contain unusually large 2026 per-share loss figures relative to reported net losses and share counts, so investors should verify those EPS fields against the company’s original filings.

11/20/26 03:59 PM ETAI Generated. May Contain Errors.

Cogent Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cogent Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cogent Biosciences' net income appears to be on a downward trend, with a most recent value of -$328.94 million in 2025, falling from -$25.49 million in 2017. The previous period was -$255.86 million in 2024. Check out Cogent Biosciences' forecast to explore projected trends and price targets.

Cogent Biosciences' total operating income in 2025 was -$333.36 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $333.36 million

Over the last 8 years, Cogent Biosciences' total revenue changed from $8.36 million in 2017 to $0.00 in 2025, a change of -100.0%.

In the past 13 quarters, Cogent Biosciences' cash and equivalents has ranged from $86.81 million in Q3 2023 to $241.21 million in Q1 2026, and is currently $217.46 million as of their latest financial filing in Q3 2026.

Cogent Biosciences had total debt of $222.90 million at the end of 2025, compared with none in 2024, and none in 2017.

Over the last 8 years, Cogent Biosciences' book value per share changed from -4.79 in 2017 to 3.84 in 2025.



Financial statements for NASDAQ:COGT last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners